Latest news


Fourth quarter and preliminary full year 2014 results

Posted on Feb 24, 2015

Lysaker, 24 February 2015 – Please find attached the presentation and report for Q4 2014 and preliminary full year 2014 results.  The presentation was held 24 February at 08:00 at Felix Konferansesenter, Oslo.  2014 4Q Report 2014 4Q Presentation This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities […]

Completion of the third group in the intra-tumour light dose escalation part of the ENHANCE study

Posted on Feb 20, 2015

Lysaker, 20 February 2015 – PCI Biotech reported today that the treatment evaluation of the third group in the intra-tumour light dose escalation part of the ENHANCE study has been completed. ENHANCE is a phase II study of Amphinex® in combination with the cytotoxic agent bleomycin in recurrent head and neck cancer patients. No safety […]

Successful completion of the second dose cohort in the study for patients with inoperable bile duct cancer

Posted on Feb 6, 2015

Lysaker, 6 February 2015 – PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the treatment evaluation of the second dose cohort is completed in the phase I/II study of Amphinex®-induced PCI of gemcitabine followed by gemcitabine/cisplatin treatment in patients with inoperable bile duct cancer (cholangiocarcinoma). No safety concerns were observed at this dose […]